tbuckley/cabot-search huggingface dataset:
Time interval as a quality measure: What is our baseline prior to nurse navigator implementation?
Authors: M. Amin, M. Basu, S. G. Patterson, H. Pinkerton, M. A. Torres, M. Newell, R. O'Regan, C. McCarthy, R. Tarpley, S. G. A. Gabram
Journal: Journal of Clinical Oncology (2011)

208 Background: There are various outcome measures to evaluate the quality of multidisciplinary care for breast cancer patients. The National Consortium of Breast Centers defines quality of breast cancer care as accurate evaluation and appropriate services in a timely manner. In a tertiary academic center a diverse referral pattern possibly influences time to treatment. We choose to examine two outcome measures before the start of a nurse navigator: Time from initial diagnosis to first consultation and if the pretreatment consultation for those receiving neoadjuvant chemotherapy or hormonal therapy included all subspecialists. Methods: Electronic medical records of female patients with breast cancer seen during January-June 2010 were reviewed. Patients with stage IV breast cancer were excluded. Results: 150 patients were divided into 4 categories: external pathology consult (B1), internally diagnosed with a primary care physician (PCP) at our institution (B2), evaluated by a surgical oncologist before the biopsy (B3), and internally diagnosed with PCP outside of the institution (B4). For B2, B3 and B4 we examined the time intervals to first surgical oncology appointment after diagnosis as shown in the table. For all patients (n=10) who received neoadjuvant therapy, 1 patient saw a surgical oncologist, medical oncologist and radiation oncologist, 9 patients saw 2 subspecialties prior to initiation of first treatment. Conclusions: Patients are seen within an average of 2 weeks whether they are diagnosed internally (B2, B3) or externally (B4). The group seen by a surgical oncologist prior to biopsy (B3) were seen sooner. For the patients receiving neoadjuvant therapy, 10% saw all 3 specialties prior to initiation of therapy. In July 2010 a nurse navigator was added to the care team. With this new position, our goal is to decrease the time from biopsy to visit by 33% and have 100% of patients receiving neoadjuvant therapy evaluated by all 3 specialists prior to treatment. Our intent is to quantify the effect of a nurse navigator in a large academic center as a quality metric in improving care. [Table: see text]
Association of Specific Dietary Fats With Mortality—Reply
Authors: Dong D. Wang, Walter C. Willett, Frank B. Hu
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Autoregulation of the Transcription Factor PU.1 Via Its Evolutionarily Conserved Upstream Regulatory Element Is Critical in Adult Mouse Hematopoiesis.
Authors: Philipp B. Staber, Pu Zhang, Min Ye, Gang Huang, Boris Bartholdy, Annalisa DiRuscio, Alexander K. Ebralidze, Daniel G. Tenen
Journal: Blood (2009)
Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study
Authors: Qian Jiang, Jianda Hu, Fang Zheng, Xin Du, Li Meng, Depei Wu, Bingcheng Liu, Zhuogang Liu, Jun Ma, Ming Hou, Sixuan Qian, Qingshu Zeng, Yu Hu, Xiaojun Huang
Journal: Blood (2016)
LAT2, a Lipid Raft Protein That Participates in AKT Phosphorylation in Mantle Cell Lymphoma, Is a Target for Perifosine Chemotherapy
Authors: Germano A Ferreira, Carolina H Thomé, Priscila Santos Scheucher, Andréia M Leopoldino, Ana Maria Simão, Clarice Izumi, Pietro Ciancaglini, Vitor Marcel Faça, Lewis Joel Greene, Guilherme A Santos, Eduardo M Rego
Journal: Blood (2014)
Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells
Authors: Baohua Sun, Warren Fiskus, Bhavin Shah, Jun Qi, Santhana G. T. Devaraj, Swaminathan Padmanabhan Iyer, Sunil Sharma, James Bradner, Youli Zu, Kapil N. Bhalla
Journal: Blood (2014)
Over-Expression of Stromal Cell-Derived Factor-1 in Non-Specialized Endothelium Enhances the Endothelium-Supported Transmigration, Maintenance, and Proliferation of Hematopoietic Progenitor Cells.
Authors: Jin-Hee Hwang, Seong-Woo Kim, Hwan-Jung Yun, Younghee Lee, Samyong Kim, Deog-Yeon Jo
Journal: Blood (2005)
Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Authors: Krina Patel, Robert Z. Orlowski, Nina Shah, Qaiser Bashir, Simrit Parmar, Yvonne T Dinh, Gabriela Rondon, Sergio A Giralt, Richard E. Champlin, Muzaffar Qazilbash
Journal: Blood (2012)
Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined analysis from two European referral institutions.
Authors: R. Sanfilippo, A. Constantinidou, R. Bertulli, P. Coco, E. Fumagalli, M. Scurr, C. Morosi, S. Pilotti, I. R. Judson, P. G. Casali
Journal: Journal of Clinical Oncology (2011)

10023 Background: Liposarcomas are the most common histological type of soft-tissue sarcomas (STS). Its main subgroups, WD/DD and MRCL, are distinct diseases with divergent morphology, genetics, and natural history as well as differential sensitivity to chemotherapy. High-dose ifosfamide (HDIFX, >12 g/m2) is active in STS pts pretreated with standard-dose IFX, though with greater toxicity. Prolonged continuous infusion (ci) HDIFX, through a portable external pump, may be an alternative regimen. Methods: From March 2002 , 51 pts (median age 57, range 30-77) with advanced disease (12 MRCL, 11 WD and 28 DD) were given ciHDIFX, at the dose of 14 g/m2 as a 14-day continuous infusion every 4 weeks. Eighteen pts were previously treated with anthracycline and ifosfamide. Results: One hundred-seventy-two cycles were delivered (median 3; range 1-8). Five patients received less than one cycle due to toxicity (they had a poor performance status) but are included in the intent-to-treat analysis. Six PR (5 in DD and 1 in a WD), 4 MR(4 in DD) and 15 SD were observed in WD/DD liposarcoma, for an overall tumor control = 60% (exceeding 70% in the patients who received at least 1 cycle). The median progression-free survival was 7 months. By contrast, 5 SD, with no PR or MR, were observed in MRCL. The median PFS in MRCL was 2 months. Most common side effects were mild myelosuppression (anemia G2-3 in 10 pts and G4 in 2 pts; G2-3 neutropenia in 8 pts and G4 in 2; G2 thrombocytopenia in 1 pt); nausea (G2-3 in 12 pts) and fatigue (G2-3 in 10 pts). One pt had a reversible G2 renal impairment. Three pts had neurotoxicity. Conclusions: These data suggest that WD/DD liposarcoma and MRCL have different sensitivity also to ciHDIFX. Contrary to the general rule, this chemotherapy seems to be more active in WD/DD. In this series, ciHDIFX regimen was better tolerated than HDIFX in published studies.
Nomograms based on the Tyrol screening data of 2,271 patients to predict prostate cancer biopsy positivity.
Authors: P. Sooriakumaran, M. John, J. Bektic, G. Bartsch, M. Herman, D. Scherr, A. Tewari
Journal: Journal of Clinical Oncology (2011)

203 Background: There are no published nomograms that predict prostate cancer in a screened population. We describe three nomograms that predict for prostate cancer on biopsy derived from a large screening population. Methods: Patients from the Tyrol screening study of known age, total prostate-specific antigen (tPSA), digital rectal examination (DRE), prostate volume, and percent free PSA (%fPSA), and who underwent an initial prostate biopsy from January 1992 to June 2004, were included (n=2271). Multivariable logistic regression models were used to develop the biopsy positivity predictive nomograms: nomogram 1- age, DRE, tPSA; nomogram 2- age, DRE, tPSA, prostate volume; nomogram 3- age, DRE, tPSA, prostate volume, %fPSA. The predictive accuracy of the models was assessed in terms of discrimination and calibration. External validation of the nomograms was performed by comparison with a urologically referred population of patients who underwent prostate biopsy (n=599). Results: All three nomograms discriminated well between biopsy positive and biopsy negative patients for both the screening and urologically referred cohorts (nomogram 3 better than nomogram 2 better than nomogram 1). All three nomograms were well calibrated internally, but the nomograms under-predicted the probability of a positive biopsy in the urologically referred cohort. Conclusions: Our nomogram based on age, total PSA, and DRE has a good predictive ability to differentiate between screened patients that will show cancer on initial prostate biopsy and those that will not. Adding prostate volume and percent free PSA improves this predictive power further. All three nomograms under-predict prostate cancer in a urologically referred cohort. These simple nomograms may be of value in counseling screened men with raised PSA and/or abnormal DRE regarding the need for biopsy. No significant financial relationships to disclose.
Effect of the orally available MET inhibitor PF-2341066 on tumor burden and metastasis in an orthotopic xenograft model of bladder cancer.
Authors: M. Sorbellini, A. Giubellino, G. Srivastava, C. Sourbier, P. A. Pinto, W. Linehan, D. P. Bottaro
Journal: Journal of Clinical Oncology (2011)

263 Background: Met over-expression has been found in bladder cancer (CaB). However, to date, the effects of Met inhibition in CaB have not been reported. We used a small, orally available, highly specific Met-inhibitor currently on phase 2 clinical trials, to assess its effects in an orthotopic xenograft model of bladder transitional cell carcinoma (TCC). Methods: An orthotopic xenograft murine model of TCC of the bladder was developed with T24-Luciferase positive bladder cancer cells. NIH 3T3 cells producing human hepatocyte growth factor (hHGF) were implanted subcutaneously in mice to provide a source of hHGF. Animals were treated with the selective Met inhibitor (PF-2341066) intra-peritoneally after positive detection of bladder tumor primary and/or metatastatic disease. Fluorescence imaging (Xenogen IVIS) of mice was performed weekly. Mice were euthanized 4 weeks after the start of treatment and their tissues studied histologically. Results: PF-2341066 was found to reduce tumor burden to below detectable levels in both primary and metastatic sites in all mice treated. No noticeable side effects were detected in treated mice secondary to drug administration. Conclusions: This study is the first to test a small orally available Met-selective inhibitor in an orthotopic, HGF-driven model of human CaB. Our results demonstrate that Met-inhibition by PF-2341066 reduces TCC tumor burden supporting its potential use in patients with bladder cancer. No significant financial relationships to disclose.
Toxicity of hypofractionated adjuvant radiation after breast-conserving surgery for DCIS.
Authors: D. Blakaj, J. L. Fox, J. Manzerova, R. Hannan, L. Hong, K. J. Mehta, S. Kalnicki
Journal: Journal of Clinical Oncology (2011)

128 Background: Traditional fractionation for whole breast radiation therapy after breast-conserving surgery has been 50Gy in 25 fractions over a 5-week period, with or without a 10 Gy boost. Hypofractionation has recently been adapted for early-stage invasive breast cancer, typically treating with 42.5 Gy in 16 daily fractions. This approach has been shown to have equivalent efficacy as the more traditional schedule. Its application to patients with DCIS has been an extrapolation of these data, and warrants further examination. This retrospective analysis reviews toxicity outcomes in women with DCIS treated with hypofractionation at our institution. Methods: 59 women with DCIS treated with lumpectomy and hypofractionated radiotherapy with or without boost between 2006 and 2010 at the Einstein-Montefiore Cancer Center were identified. Median age was 65 (39-85). Median follow-up was 13.7 months (2–37.6). Surgical margin status was negative in 55, positive in 1, and unknown in 3. Thirteen patients had high-grade DCIS, 17 intermediate-grade, and 13 low-grade nuclear features, and 16 did not have grade delineation. 68% of patients (40 women) had disease that was positive both for ER and PR receptors, 2 women were simultaneously positive for ER and PR, 5 women had ER-only positive disease, 2 women had HER2-neu-only positive disease, 1 woman was positive for both ER and HER2-neu receptors, 1 woman was positive only for PR receptors, and 6 women were negative for all receptors; receptor status of specimens from 2 patients is not known. All women were treated with whole-breast hypofractionated therapy (42.4 Gy, in 16 fractions of 2.65 Gy each). 49 women received a boost to the lumpectomy cavity consisting of 10Gy in 5 fractions or 9.6 Gy in 4 fractions at the physician’s discretion. Results: With this regimen, no patient experienced acute RTOG grade 3 or higher skin, or other toxicity. No treatment breaks were required due to toxicity. The most common side effects were grade 1 dermatitis, followed by grade 2 dermatitis with mild edema of the treated breast. Conclusions: Our results suggest that postoperative hypofractionated radiation to the breast is well tolerated by women with DCIS and does not result in untoward acute toxicity.
Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis
Authors: S Weber, T Haferlach, C Haferlach, W Kern
Journal: Blood Cancer Journal (2016)

Comprehensive study on  ERG  gene expression in normal karyotype acute myeloid leukemia:  ERG  expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Authors: Charles M Rudin, M Catherine Pietanza, Todd M Bauer, Neal Ready, Daniel Morgensztern, Bonnie S Glisson, Lauren A Byers, Melissa L Johnson, Howard A Burris, Francisco Robert, Tae H Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K Strickland, Ramaswamy Govindan, Scott J Dylla, Stanford L Peng, David R Spigel
Journal: The Lancet Oncology (2016)
Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era.
Authors: Ruben A. Mesa, Susan Schwager, Jocelin Huang, Animesh D. Pardanani, Kebede Hussein, John Camoriano, Ayalew Tefferi
Journal: Blood (2009)
A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells
Authors: Dharminder Chauhan, Ajita V. Singh, Arghya Ray, Teru Hideshima, Paul G. Richardson, Michael A. Palladino, Kenneth C. Anderson
Journal: Blood (2011)
Arrhythmogenic Right Ventricular Cardiomyopathy
Authors: Andrea Mazzanti, Kevin Ng, Alessandro Faragli, Riccardo Maragna, Elena Chiodaroli, Nicoletta Orphanou, Nicola Monteforte, Mirella Memmi, Patrick Gambelli, Valeria Novelli, Raffaella Bloise, Oronzo Catalano, Guido Moro, Valentina Tibollo, Massimo Morini, Riccardo Bellazzi, Carlo Napolitano, Vincenzo Bagnardi, Silvia G. Priori
Journal: Journal of the American College of Cardiology (2016)
Anti-Acute Myeloid Leukemia Activity of Chaetocin, a Novel Epigenetic Drug Inhibitor Inducing Oxidative Stress.
Authors: Hassiba Chaib, Thomas Prebet, Audrey Restouin, Remy Castellano, Sandrine Opi, Daniel Olive, Jean Paul Borg, Norbert Vey, Yves Collette
Journal: Blood (2007)
Injection of hyaluronic acid (HA) to better preserve the rectal wall in prostate hypofractionated radiotherapy (HFR).
Authors: Olivier Chapet, Corina M Udrescu, Alain Ruffion, Marie-Pierre Sotton, Marian Devonec, Marion Vincent, Nabil Zahra, Christophe Mazzara, Marc Colombel, David Azria, Patrice Jalade
Journal: Journal of Clinical Oncology (2012)

202 Background: Several studies are in favor of an α/β ratio of less than 3Gy for prostate (P) cancer, encouraging HFR. However, the development of such radiation patterns can only be done if the risk of rectal toxicity is well controlled. The objective of the present study was to evaluate the contribution of an injection of HA between the rectum and the P to reduce the risk of rectal toxicity in a HFR approach. Methods: A phase II study of HFR at 62Gy in 20 fractions (BED = 84Gy; α / β = 1.5Gy) is currently conducted. A transperineal injection of 10cc of HA (NASHA Spacer gel, Q-Med AB, Uppsala, Sweden) is systematically performed, between the rectum and the P, under local anesthesia and under ultrasound guidance. A dosimetric CT scan is performed before (CT1) and after injection (CT2). Patients are treated with a 7 beams IMRT plan, optimized on the CT2. For the first 10 patients included in the study, the same treatment plan was optimized on CT1. The rectum was empty on the 2 CTs and defined from 2cm above the seminal vesicles to 2 cm below the P. The rectal wall was defined by an internal expansion of 5 mm. The volumes of rectum irradiated, with and without HA, were compared on the following dosimetric parameters: maximum dose (D max), dose to 2.5cc (D2.5), 5cc (D5) and 10cc (D10) of rectal wall and volume of rectum receiving 90% (V90), 80% (V80) and 70% (V70) of the prescribed dose of 62Gy. To limit a potential impact of variation of rectal volume between the two CT, all results are given in cc and not in % of volume. Results: The mean P volume was 52.4cc (30cc - 93.8cc) on the CT1 and 52cc (32.5 - 92.7) on the CT2. The injection of HA reduced the mean D max value to the rectal wall of 4.5Gy (57.5Gy vs 62 Gy). The mean values of V90, V80, and V70 are reduced by 69% (1.9cc vs 6.1cc), 46% (4.5cc vs 8.4cc) and 32% (7.4cc vs 10.9cc). Same way, the average values of D2.5, D5 and D10 are reduced by 6.2 Gy (54.6Gy vs 60.8Gy) 9.3Gy (49.0Gy vs 58.3Gy) and 7.8Gy (39.7Gy vs 47.5Gy). Conclusions: In this study, the injection of HA limited the doses to the rectal wall. These results suggest that late toxicities could be significantly reduced. A phase II study is underway to assess the rate of late rectal toxicities when a HFR at 62Gy in 20 fractions is combined with an injection of HA.
Inhibition of 3β-hydroxysteroid dehydrogenase by abiraterone as a rationale for dose escalation in castration-resistant prostate cancer.
Authors: Nima Sharifi, Rui Li, Kristen Evaul, Kamalesh Sharma, Richard J Auchus
Journal: Journal of Clinical Oncology (2012)

209 Background: Treatment with abiraterone acetate (abi) increases the survival of men with castration-resistant prostate cancer (CRPC). Resistance to abi invariably occurs, probably due in part to up-regulation of steroidogenic enzymes and/or other mechanisms that sustain the synthesis of dihydrotestosterone (DHT), which raises the possibility of reversing resistance by concomitant inhibition of other required steroidogenic enzymes. The 1000 mg daily abi dose was selected for the phase III trials despite the absence of dose-limiting toxicities at higher doses. Based on the 3β-hydroxyl, Δ 5 -structure, we hypothesized that abi also inhibits 3β-hydroxysteroid dehydrogenase/isomerase (3βHSD), which is absolutely required for the intratumoral synthesis of DHT in CRPC, regardless of origins or routes of synthesis. Methods: We tested if abi inhibits recombinant 3βHSD2 activity in vitro or endogenous 3βHSD activity in LNCaP and LAPC4 cells, including conversion of [ 3 H]-dehydroepiandrosterone (DHEA) to androstenedione (AD), androgen receptor (AR) nuclear translocation, expression of AR-responsive genes, and LAPC4 xenograft growth in orchiectomized mice supplemented with DHEA. Results: Abi has a mixed inhibition pattern of 3βHSD2 in vitro, blocks the conversion from DHEA to AD and DHT with an IC 50 of &lt; 1 µM in CRPC cell lines, inhibits AR nuclear translocation and expression of TMPRSS2, and decreases CRPC xenograft growth in DHEA-supplemented mice. Conclusions: Abi blocks 3βHSD enzymatic activity, synthesis of AD and DHT, inhibits the AR-response, and suppresses growth of CRPC cells at concentrations that are clinically achievable. Variable abi inhibition of 3βHSD might account in part for the heterogeneous clinical response to abi. More importantly, 3βHSD inhibition with abi might be clinically harnessed to reverse resistance to CYP17A1 inhibition at the standard dose by dose-escalation, or simply by administration with food to increase drug exposure.
Does Donor Epstein-Barr Virus (EBV) Seropositivity Affect Recipient's Risk of Graft Versus Host Disease (GVHD) in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)?
Authors: Erden Atilla, Esmanur Kaplan, Pinar Ataca Atilla, Selami Kocak Toprak, Pervin Topcuoglu, Hamdi Akan
Journal: Blood (2016)